Teva Pharmaceutical Industries Ltd (TEVA)
13.01
0.00 (0.00%)
USD |
NYSE |
Apr 24, 16:00
12.85
-0.16
(-1.23%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 14.59B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 55.81% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.9214 |
Price to Book Value | 1.943 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 2.642 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 90.81% |
Profile
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor. |
URL | https://www.tevapharm.com |
Investor Relations URL | https://ir.tevapharm.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Mid Cap/Value |
Next Earnings Release | May. 08, 2024 |
Last Earnings Release | Jan. 31, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Nov. 27, 2017 |
Ratings
Profile
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor. |
URL | https://www.tevapharm.com |
Investor Relations URL | https://ir.tevapharm.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Mid Cap/Value |
Next Earnings Release | May. 08, 2024 |
Last Earnings Release | Jan. 31, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Nov. 27, 2017 |